Plantimex Recalls Mamisan Lidocaine Ointment Containers Due to Risk of Serious Injury or Death from Child Poisoning; Violates Mandatory Standard for Child-Resistant Packaging

  • The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The ointment's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.
  • Company: Plantimex
  • Over-the-Counter Medications
  • CPSC
  • December 18, 2025

Product details

  • Mamisan Pain Relieving Topical Ointment

Company announcement

Plantimex is recalling Mamisan Pain Relieving Topical Ointment due to the risk of serious injury or death from child poisoning.

The ointment's packaging is not child-resistant, violating the Poison Prevention Packaging Act.

The product was sold at Walmart and Target stores nationwide and online. No incidents or injuries have been reported.

The recall date is December 18, 2025.

Risk:

The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The ointment’s packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.

Impacted states: Nationwide

Products:

- Mamisan Pain Relieving Topical Ointment (UPC code(s): 860006498115)

Contact

For more information, call 855-752-6869 or email customercare@plantimexusa.com.

View the original CPSC notice

Browse all recalls